My overall research goal is to identify genetic biomarkers and clinical and demographical characteristics associated with treatment outcomes (i.e. response and remission) in major depressive disorder (MDD). When I started my postdoctoral training, I was invited to join the Canadian Biomarker Integration Network in Depression (CAN-BIND) study, which consists of several centers across Canada, which investigates the precise role of gene variants, microRNAs, protein expression and oxidative stress to find biomarkers for treatment response in depression. I believe such investigations will expand knowledge about SNRIs treatment outcomes, which are under investigated when compared to SSRIs. As a member of the Canadian Biomarker Integration Network in Depression (CAN-BIND) Group, I hope to contribute to our goal to reduce burden of depression and improve its treatment.
No posts yet.